Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    France Poland
  • Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    France Italy
  • Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    France Greece Hungary Italy Poland Spain
  • Study of E7386 and Pembrolizumab for Patients with Previously Treated Colorectal Cancer, Melanoma, or Hepatocellular Carcinoma

    Not recruiting

    1 1 1 1
    Spain
  • Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    Norway Slovakia Sweden
  • Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    Austria Denmark Finland France Germany Italy +3
  • Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    Austria Belgium Czechia France Germany Hungary +6
  • Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    Austria Belgium Denmark Finland France Germany +7
  • Study of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    France Spain
  • Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Belgium Spain